The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

Provided herein is a portable test device, mass manufacture method and method of use for identification of at least one target drug of abuse. The portable detection kit can include a catalytic reagent, a solid support carrier, and an absorbent material. The colorimetric reagent and the catalytic reagent can be are affixed to the solid support carrier to form a reaction zone thereon. The colorimetric reagent and the catalytic reagent are configured to undergo chemical reaction with at least one target drug of abuse to produce a visible color change. The at least one target drug of abuse is selected from the group consisting of nicotine, cannabinoids, amphetamines, opioids, or cocaine. A target drug of abuse can be on vaping device surfaces and/or within vaping liquid formulations.

The present technology is directed to compounds, compositions, and methods related to non-morphinan-like mu opioid receptor agonists. Compounds of the present technology demonstrate remarkable potency and selectivity for the mu opioid receptor over the kappa opioid receptor, while also exhibiting a significant reduction (or, essentially, absence) of the negative side effects of many morphine-derived compounds.

The present invention relates to a device and a method for analysing a sample comprising from 0.1 pg to 1 μg of analyte, and more specifically to a lateral flow device and a method for testing the presence of very low amounts of drugs or drug meta bolites in a sample. The present invention also relates to a method of dissolving a bodily fluid.

Described herein is a method to induce surface trafficking of the delta-Opioid Receptor (DOR) and its applications, including, leveraging the antinociceptive potential of DOR agonists to treaty neurologic disorders and to be analgesics without the adverse consequences normally associated with chronic treatment by MOR agonists by inducing surface trafficking of the delta-Opioid Receptor (DOR) and screening compounds to identify additional targets for stimulated DOR delivery.

Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine at the 3-position of one of the phenyl rings. Antibodies produced from immunogenic EDDP conjugates and labeled EDDP conjugates are employed in assays for determining the presence and/or amount of EDDP in samples suspected of containing EDDP.

Compounds of formula: ##STR00001##
in which R.sup.4 is chosen from substituted phenyl, optionally substituted naphthylene, optionally substituted anthracene and optionally substituted aromatic heterocycle, are useful as analgesics.

A highly portable, paper and swab-based detection kit is provided for identifying Amphetamine, Cannabis, Cocaine, Heroin, selected synthetic Cannabinoid, and amphetamine based Cathinone type stimulants, and cannabis consumable products. A method of mass manufacture providing low cost kits with long term commercial shelf life and a method of use are also provided.

Embodiments for local and safe testing of injection fluids by drawing a sample of injection fluid into a local test chamber while drawing fluid to be tested into a syringe assembly and testing the sample of the injection fluid are disclosed. A fluid test device can include a syringe assembly, a plunger assembly, and a test module. The test module can determine information about fluid in a syringe assembly when the fluid enters a test chamber in the test module. Fluid may enter the test chamber through a one-way valve while a plunger in the plunger assembly is moved in a suction stroke to draw fluid into an interior of the syringe assembly. Fluid may not enter or be expelled from the test chamber when the plunger does not move or is moved in a compression stroke to expel fluid from the syringe assembly.

Compositions and methods are provided for use in binding opioids, such as 6-MAM, morphine, heroin, hydrocodone, oxycodone, meperidine, and fentanyl, while avoiding binding to OUD treatment agents, such as naloxone and naltrexone. Methods are also provided for use in a systematic structure-based virtual screening and design approach for identification of such antibodies. Methods are also provided for use in treating OUD. Methods are also provided for use in detecting an opioid in a sample.